A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1)

General Information

Clinical trials phase Phase 1
Start date (estimated) 2023-01-24
End date (estimated) 2027-08-31
Clinical feature
Label B-Cell Malignant Neoplasm
Link http://purl.obolibrary.org/obo/NCIT_C188021
Description A clonal lymphoproliferative disorder composed of neoplastic B-cells. It includes B-cell non-Hodgkin lymphomas, B-cell leukemias, and plasma cell myeloma.

Administrative Information

NCT number NCT05336409
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05336409
Other study identifiers
Name CNTY-101-111-01 (ELiPSE-1)
Source weblink https://clinicaltrials.gov/ct2/show/NCT05336409
Public contact
Email ntrede@centurytx.com
Public email ntrede@centurytx.com
First name Nikolaus
Last name Trede
Phone +1 888-506-7670
United States
Sponsors Century Therapeutics, Inc.


Which differentiated cell type is used
Label natural killer cell
Link http://purl.obolibrary.org/obo/CL_0000623
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Recruiting
Estimated number of participants 75